Skip to main content

Dianthus Therapeutics, Inc. /DE/

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

DNTH$90.00+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

DIANTHUS THERAPEUTICS, INC.
Date:March 9, 2026By:/s/ Ryan Savitz
Ryan Savitz
Executive Vice President, Chief Financial Officer and Chief Business Officer
(Principal Financial Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marino Garcia, Ryan Savitz and Adam Veness, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the Dianthus Therapeutics, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Marino GarciaPresident, Chief Executive Officer and Director(Principal Executive Officer)March 9, 2026
Marino Garcia
/s/ Ryan SavitzExecutive Vice President, Chief Financial Officer and Chief Business Officer(Principal Financial Officer)March 9, 2026
Ryan Savitz
/s/ Edward CarrChief Accounting Officer (Principal Accounting Officer)March 9, 2026
Edward Carr
/s/ Alison LawtonDirector and Chair of the BoardMarch 9, 2026
Alison Lawton
/s/ Sujay KangoDirectorMarch 9, 2026
Sujay Kango
/s/ Anne McGeorgeDirectorMarch 9, 2026
Anne McGeorge
/s/ Steven Romano, M.D.DirectorMarch 9, 2026
Steven Romano, M.D.
/s/ Simon Read, Ph.D.DirectorMarch 9, 2026
Simon Read, Ph.D.
/s/ Paula SoteropoulosDirectorMarch 9, 2026
Paula Soteropoulos
/s/ Jonathan Violin, Ph.D.DirectorMarch 9, 2026
Jonathan Violin, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.